Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Veterinary science

Veterinary science

Transforming veterinary research using data science, one paw at a time

Data science is vastly changing the way we do research. Veterinary research is, however, still lagging behind its human counterpart. Why is this the case and can we learn from human health data to close this gap?

Bridging the immunity gap: improving animal welfare without antibiotics

Antibiotic resistance is a major concern for humans and animals. Increasing pressure to move away from antibiotics has created space for new solutions for disease management. Animab’s oral monoclonal antibody platform is a promising alternative, effectively guarding against infection during a vulnerable period in an animal’s development.

Data science: empowering animal-free progress in preclinical development

Many drugs fail clinical trials, often because preclinical animal models fall short of replicating human physiology. To improve animal welfare, speed up drug development, and reduce costs, we need to rely less on animal models, while also minimizing the number of failures early in the drug development process. Artificial intelligence and machine learning are powerful tools that can help us achieve these goals by predicting a drug's efficacy, safety, and uptake in preclinical studies. These technologies can help researchers to make informed decisions and optimize testing strategies, improving drug development for both animals and people.

RE-Place project: Reducing animal research through alternative methods

If scientists could stop animal testing, most would do so immediately. So why is it taking so long to develop alternatives to animal testing? And what are we doing to speed up the process?

Saving man’s best friend: Volition blood test allows cheap and easy cancer screenings for dogs

A Belgian invention is revolutionizing cancer diagnostics for dogs by making it possible to screen for two common canine cancers with a simple, low-cost blood test. The innovation was developed by the Belgian subsidiary of Volition, a multinational company listed on the New York stock exchange. The company is also developing human blood tests for use in oncology as well as a number of other diseases including COVID-19.

Prestigious prize for Belgian breakthrough in brain research

Prof. Dr. Pierre Vanderhaeghen from VIB-KU Leuven has been awarded the Generet Prize for Rare Diseases for his research on human brain development. Vanderhaegen’s team have developed an astonishing model for studying rare neurological disorders by successfully integrating human neurons into a mouse brain. The prestigious prize, managed by the King Baudouin Foundation and presented to Vanderhaeghen by HRH Princess Astrid, includes EUR 1 million in funding for further studies.

V-Bio Ventures invests in new start-up Animab in a EUR 3.4 million Seed Financing to improve health and performance of livestock animals

Gent, Belgium, 27 October 2020 – Today V-Bio Ventures announces its investment in Animab, a new venture spin-off from VIB, in a EUR 3.4 million Seed financing round. The company develops monoclonal antibodies for oral administration to ensure intestinal health of livestock. The initial focus is on improving the resilience of piglets during the fragile post-weaning period. The start-up will use the seed capital to develop its first oral antibody product for protection against ETEC and initiate a product portfolio for the livestock industry.

Belgian stem cell company GST bought by German pharmaceutical giant

The German pharmaceutical giant Boehringer Ingelheim has acquired GST, a stem cell specialist based in Belgium. A part of the Anacura Group, GST’s main focus is in animal health, with its main product being a stem cell therapy for injured horses. Despite the acquisition, the company will remain in its labs near Ghent, keeping its research and production rooted in Flemish soil.

Anacura, a Belgian biotech company, sells stem cell business to Boehringer Ingelheim

Ghent, Belgium, 27 July 2020 – GST, the stem cell specialist for horses and pets within the Anacura Group, has been acquired by Boehringer Ingelheim. The acquisition follows two years of successful cooperation. Research and production will continue in Anacura’s labs, close to Ghent, Belgium. The current management and staff will play a crucial role in the implementation and further development of stem cell technology within Boehringer Ingelheim.

To prevent another pandemic, we need to improve our relationship with animals

Belgian initiatives boosting animal-free innovation

Animals have been used throughout history to understand human physiology and to resolve scientific questions related to health and disease. Nowadays, however, both scientists and the public are pushing for better options to animal testing, and so increasing efforts are being put into developing and promoting these alternative methods. Two such initiatives are being spearheaded by the Vrije Universiteit Brussel (VUB): The Innovation Centre for 3R Alternatives (IC-3Rs) and the RE-Place project.